Acquisition Interest Stada Group has publicly considered a potential acquisition of Cooper Consumer Health for around €6B, signaling a high interest from large European players and potential partner-led expansion opportunities for sales leverage, licensing, and distribution negotiations.

CEE Expansion Cooper Consumer Health has partnered with MagnaPharm to distribute and commercialise its self-care brand portfolio in Central and Eastern Europe starting January 2025, presenting a clear channel for entering new markets and cross‑sell of OTC lines through established regional networks.

European OTC Growth With a diversified OTC portfolio including Vitascorbol, Valdispert, Excilor, Oenobiol and more, distributed to over 80,000 pharmacies across Europe, there is substantial opportunity to accelerate co‑marketing, private-label opportunities, and targeted campaigns with retailers and pharmacy chains.

Digital & CRM Upsell Existing tech stack ( Salesforce, Marketing Cloud, Shopify, WordPress, AWS) enables targeted omnichannel campaigns and e‑commerce enablement for new product launches, enabling sales teams to run data‑driven promotions and direct consumer offers across EU markets.

Financial runway Revenue is currently in the $1M–$10M range with a financially stable profile and a parent platform emphasizing ownership mindset and innovation, suggesting readiness for scalable partnerships, co‑funded launches, and performance-based distribution deals.